Basilea enters into agreement with BARDA to develop novel antifungals and antibacterials and receives initial funding - Marketscreener.com
BPMUF Stock | USD 52.83 0.00 0.00% |
Roughly 56% of Basilea Pharmaceutica's investor base is looking to short. The analysis of overall sentiment of trading Basilea Pharmaceutica AG pink sheet suggests that many investors are alarmed at this time. The current market sentiment, together with Basilea Pharmaceutica's historical and current headlines, can help investors time the market. In addition, many technical investors use Basilea Pharmaceutica stock news signals to limit their universe of possible portfolio assets.
Basilea Pharmaceutica pink sheet news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Basilea daily returns and investor perception about the current price of Basilea Pharmaceutica AG as well as its diversification or hedging effects on your existing portfolios.
Basilea |
Basilea enters into agreement with BARDA to develop novel antifungals and antibacterials and receives initial funding Marketscreener.com
Read at news.google.com
Basilea Pharmaceutica Fundamental Analysis
We analyze Basilea Pharmaceutica's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Basilea Pharmaceutica using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Basilea Pharmaceutica based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Asset
Current Asset Comparative Analysis
Basilea Pharmaceutica is currently under evaluation in current asset category among its peers. Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Basilea Pharmaceutica Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Basilea Pharmaceutica pink sheet to make a market-neutral strategy. Peer analysis of Basilea Pharmaceutica could also be used in its relative valuation, which is a method of valuing Basilea Pharmaceutica by comparing valuation metrics with similar companies.
Peers
Basilea Pharmaceutica Related Equities
RVPH | Reviva Pharmaceuticals | 18.87 | ||||
DNA | Ginkgo Bioworks | 3.08 | ||||
CVAC | CureVac NV | 2.80 | ||||
BNTX | BioNTech | 1.51 | ||||
PRQR | ProQR Therapeutics | 1.51 | ||||
BPMC | Blueprint Medicines | 0.87 | ||||
WVE | Wave Life | 0.40 | ||||
ALNY | Alnylam Pharmaceuticals | 0.15 | ||||
CRSP | Crispr Therapeutics | 0.47 | ||||
NVAX | Novavax | 0.57 | ||||
APLS | Apellis Pharmaceuticals | 1.09 | ||||
EYPT | Eyepoint Pharmaceuticals | 1.18 | ||||
PLX | Protalix Biotherapeutics | 1.64 | ||||
SLS | Sellas Life | 4.59 | ||||
MRNA | Moderna | 9.07 |
Complementary Tools for Basilea Pink Sheet analysis
When running Basilea Pharmaceutica's price analysis, check to measure Basilea Pharmaceutica's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Basilea Pharmaceutica is operating at the current time. Most of Basilea Pharmaceutica's value examination focuses on studying past and present price action to predict the probability of Basilea Pharmaceutica's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Basilea Pharmaceutica's price. Additionally, you may evaluate how the addition of Basilea Pharmaceutica to your portfolios can decrease your overall portfolio volatility.
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |